However, while in CM the MAPK cascade is directly activated by a constitutive alteration of one of its component (BRAF or NRAS), in MM the oncogenic MAPK activation is indirectly promoted by effectors external to the pathway (KIT and/or NF1) (Figure 1). This evidence concerns the gene KIT and Miyoshi myopathy.